Ann: Bioshares Biotech Summit Presentation-RAP.AX, page-66

Currently unlisted. Proposed listing date: 4 SEPTEMBER 2024 #

First 66 Last

Share
Profile

Follow
dman0

2,744 Posts.

1320

02/08/16

16:18

Post #: 18427451
Share

Originally posted by ScrimpyCat ↑

Well the only stream (to my knowledge) that could be reversible (has the algorithm on the device) would be the humanitarian stream. Since network connectivity is often spotty at best when they're doing field testing, so having it locally on the device would be important. Soon my way someone is going be able to reverse it is if they get it from these organisations. So I really feel like this concern about reversing isn't really what people should be concerned about. It's much more likely someone will just read the research papers, and do their own testing/create their own implementation from that (and even if that happens we still have an advantage as they will be playing catchup essentially).

But as far as your question. Basically ML (machine learning) algorithms can improve overtime when they have more data. That in and of itself doesn't make reversing the algorithm anymore difficult. Rather it's just advantageous if we have more cough data than a competitor (that is using the same technique). So if we have more data than a competitor who is using the same algorithm, then our diagnosis can be more accurate and may possibly cover more diseases.

Expand

I don't know anything about computer programing, C++ or whatever, but I have travelled a lot, and often to developing countries. About 10years ago I stopped being amazed that the mobile phone and data coverage in these places is so much better than regional/rural Australia. I don't think you should assume that the algorithm would need to be on the device.

RAP Price at posting: 36.0¢ Sentiment: Buy Disclosure: Held
4 Upvote

0 Great analysis

Reply

Top Stories

88E

HotCopper users smell capital raising as 88 Energy says "significant update" at Phoenix

HVN

Harvey Norman clocks subdued gains as Echo Law's junk warranty class action kicks off

BPM

BPM Minerals hits high-grade gold at the Claw Project WA; shares jump 86%

CXU

Cauldron discovers shallow uranium up to 2km at WA's Yanrey

PAR

FDA hands Paradigm Biopharma guidance to re-jig phase 3 osteo trial – or is it a delay?